By Jake King
In a press release Monday, BioSante Pharmaceuticals (NASDAQ:BPAX) announced that it will be presenting a corporate update at the BIO Investor Forum on Wednesday the 10th; the presentation will likely focus on the company’s recent merger with ANI Pharmaceuticals and shed light on the details of the agreement. PropThink covered that event last week, which we consider a good deal for ANI. We believe BPAX will decline further, however, based on dilution and a lower intrinsic value in BioSante shares. Read PropThink’s previous coverage by clicking the link above, or by clicking here.
